X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (46) 46
neuroblastoma (45) 45
humans (42) 42
article (35) 35
oncology (34) 34
infant (30) 30
female (29) 29
male (28) 28
child (25) 25
child, preschool (23) 23
pediatrics (20) 20
cancer (19) 19
tumors (18) 18
children (16) 16
prognosis (14) 14
neuroblastoma - genetics (13) 13
neuroblastoma - pathology (13) 13
research (13) 13
neoplasm staging (12) 12
chemotherapy (11) 11
adolescent (10) 10
diagnosis (10) 10
hematology (10) 10
neuroblastoma - mortality (10) 10
neuroblastoma - therapy (10) 10
patients (10) 10
risk (10) 10
risk groups (10) 10
survival (10) 10
disease-free survival (9) 9
genetic aspects (9) 9
neuroblastoma - drug therapy (9) 9
survival rate (9) 9
abridged index medicus (8) 8
risk factors (8) 8
surgery (8) 8
classification (7) 7
clinical trials (7) 7
health aspects (7) 7
immunotherapy (7) 7
medical colleges (7) 7
mibg (7) 7
mycn (7) 7
treatment outcome (7) 7
wilms tumor (7) 7
age (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
expression (6) 6
gene-expression (6) 6
induction chemotherapy (6) 6
infant, newborn (6) 6
kidney neoplasms - pathology (6) 6
neuroblastoma - metabolism (6) 6
radiology, nuclear medicine & medical imaging (6) 6
stem cells (6) 6
young adult (6) 6
analysis (5) 5
cell line, tumor (5) 5
children & youth (5) 5
follow-up studies (5) 5
gene amplification (5) 5
gene expression (5) 5
genetics & heredity (5) 5
immunohistochemistry (5) 5
immunology (5) 5
international neuroblastoma pathology classification (5) 5
medical research (5) 5
national wilms-tumor (5) 5
nephroblastoma (5) 5
neuroblastoma - diagnostic imaging (5) 5
nuclear medicine (5) 5
nuclear proteins - genetics (5) 5
retrospective studies (5) 5
risk assessment (5) 5
adult (4) 4
amplification (4) 4
animals (4) 4
biopsy (4) 4
case-parent triad (4) 4
colony-stimulating factor (4) 4
combined modality therapy (4) 4
confidence intervals (4) 4
curie score (4) 4
cytokines (4) 4
disease progression (4) 4
gene expression profiling (4) 4
genetics (4) 4
hematology, oncology and palliative medicine (4) 4
high-risk neuroblastoma (4) 4
imaging / radiology (4) 4
kaplan-meier estimate (4) 4
kidney neoplasms - surgery (4) 4
logistic models (4) 4
loss of heterozygosity (4) 4
medicine & public health (4) 4
metastatic neuroblastoma (4) 4
n-myc (4) 4
n-myc proto-oncogene protein (4) 4
nephrectomy (4) 4
neuroblastoma - diagnosis (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 946 - 957
Summary Background Outcomes for children with relapsed and refractory neuroblastoma are dismal. The combination of irinotecan and temozolomide has activity in... 
Hematology, Oncology and Palliative Medicine | Dacarbazine - adverse effects | Humans | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | N-Myc Proto-Oncogene Protein - genetics | Neoplasm Recurrence, Local - drug therapy | Infant | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Pain - chemically induced | Fever - chemically induced | Infection - chemically induced | Ganglioneuroblastoma - diagnostic imaging | Neoplasm Recurrence, Local - diagnostic imaging | Hypokalemia - chemically induced | Dacarbazine - analogs & derivatives | Camptothecin - administration & dosage | Ganglioneuroblastoma - drug therapy | Neutropenia - chemically induced | Child | Sirolimus - adverse effects | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Dacarbazine - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | Sirolimus - analogs & derivatives | Ganglioneuroblastoma - genetics | Neuroblastoma - genetics | Anemia - chemically induced | Neuroblastoma - diagnostic imaging | Survival Rate | Thrombocytopenia - chemically induced | Disease-Free Survival | Retreatment | Sirolimus - administration & dosage | Gene Amplification | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroblastoma - drug therapy | Adolescent | Neoplasm Recurrence, Local - genetics | Hypoxia - chemically induced | Medical colleges | Stem cells | Neuroblastoma
Journal Article
Nature genetics, ISSN 1061-4036, 2015, Volume 47, Issue 8, pp. 864 - 871
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 7, pp. 663 - 671
Journal Article
Cancer, ISSN 0008-543X, 12/2017, Volume 123, Issue 24, pp. 4914 - 4923
BACKGROUND Early‐phase trials in patients with recurrent neuroblastoma historically used an objective “response” of measureable disease (Response Evaluation... 
prognostic | historical standard | endpoints | phase 2 design | International Neuroblastoma Response Criteria (INRC) | Response Evaluation Criteria In Solid Tumors (RECIST) | SYSTEM | DIAGNOSIS | PROGNOSIS | RISK GROUP | RELAPSE | PATHOLOGY CLASSIFICATION | INTERNATIONAL CRITERIA | ONCOLOGY | STRATIFICATION | AGE | Follow-Up Studies | United States | Humans | Child, Preschool | Antibodies, Monoclonal - therapeutic use | Infant | Male | Response Evaluation Criteria in Solid Tumors | Neuroblastoma - mortality | Neuroblastoma - therapy | Neoplasm Recurrence, Local - mortality | Cause of Death | Neoplasm Recurrence, Local - pathology | Female | Child | Neuroblastoma - pathology | Medical Oncology - methods | Risk Assessment | Neoplasm Recurrence, Local - therapy | Treatment Outcome | Combined Modality Therapy | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Usage | Oncology | Development and progression | Transplantation | Research | Neuroblastoma | Children | Health aspects | Hematopoietic stem cells | Therapy | Clinical trials | Stem cell transplantation | Standard error | Bone tumors | Design | Historical account | Bone marrow | Risk groups | Benchmarks | Patients | Survival | Hemopoiesis | Children & youth | Heterozygosity | Studies | Loss of heterozygosity | Stem cells | Bone | Solid tumors | Tumors | Cancer
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 01/2020, Volume 67, Issue 1, p. n/a
Background GD2 is a ganglioside that is ubiquitously expressed in the plasma membrane of neuroblastoma and is shed into the circulation. Procedure GD2 was... 
neuroblastoma | biomarker | ganglioside | Biomarkers | Mass spectroscopy | Risk | Liquid chromatography | Diagnostic systems | Neuroblastoma | Children | Diagnosis | Mass spectrometry | Fatty acids | Tumors
Journal Article
Cancer, ISSN 0008-543X, 11/2017, Volume 123, Issue 21, pp. 4224 - 4235
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2018, Volume 24, Issue 1, pp. 189 - 196
Journal Article
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, ISSN 0098-7484, 08/2019, Volume 322, Issue 8, pp. 746 - 755
Journal Article
PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 4, p. e18557
Journal Article
Journal of the American Statistical Association, ISSN 0162-1459, 03/2013, Volume 108, Issue 501, p. 202
  This article proposes an extended state-space model for accommodating multivariate panel data. The novel aspect of this contribution is an adjustment to the... 
Parameter estimation | Algorithms | Simulation | Normal distribution | Maximum likelihood method
Journal Article